Publication Name	World Journal of Hepatology
Manuscript ID	3957
Country	Canada

Received	2013-06-04 19:32
Peer-Review Started	2013-06-05 09:44
First Decision by Editorial Office Director
Return for Revision	2013-07-17 15:48
Revised
Publication Fee Transferred
Second Decision by Editor	2013-10-16 11:14
Second Decision by Editor-in-Chief
Final Decision by Editorial Office Director	2013-10-16 12:04
Articles in Press
Edit the Manuscript by Language Editor
Typeset the Manuscript	2013-10-23 18:33
Publish the Manuscript Online	2013-10-25 08:47

ISSN	1948-5182 (online)
Open Access
Copyright
Article Reprints	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
Permissions	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
Publisher	Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Website	http://www.wjgnet.com

Category	Gastroenterology & Hepatology
Manuscript Type	Case Report
Article Title	Severe cholestasis due to adalimumab in a Crohn’s disease patient
Manuscript Source	Invited Manuscript
All Author List	Edward Kim, Brian Bressler, David F Schaeffer and Eric M Yoshida
Funding Agency and Grant Number
Corresponding Author	Eric M Yoshida, MD, Professor of Medicine, Head, Division of Gastroenterology, University of British Columbia, 2775 Laurel Street, Vancouver, BC V5Z 1M9, Canada. eric.yoshida.@vch.ca
Key Words	Crohn’s disease; Cholestasis; Adalimumab; Anti-tumor necrosis factor agents; Drug-induced liver injury
Core Tip	Anti-tumor necrosis factor agents are commonly used in the treatment of inflammatory bowel disease and other inflammatory conditions. Drug-induced injury to the liver induced by the agents includes autoimmune hepatitis, direct hepatocellular necrosis and cholestasis. Our patient, a 39-year-old female with Crohn’s disease, developed severe jaundice after initiation of adalimumab. We present the first report of adalimumab-associated severe cholestatic injury and the first histopathologic examination of this adverse drug effect. Clinicians need to be aware of this potential severe drug-induced liver injury when prescribing this commonly used biologic medication.
Publish Date	2013-10-25 08:47
Citation	Kim E, Bressler B, Schaeffer DF, Yoshida EM. Severe cholestasis due to adalimumab in a Crohn’s disease patient. World J Hepatol 2013; 5(10): 592-595
URL	http://www.wjgnet.com/1948-5182/full/v5/i10/592.htm
DOI	http://dx.doi.org/10.4254/wjh.v5.i10.592

Full Article (PDF)	WJH-5-592.pdf
Manuscript File	3957-Review.doc
Answering Reviewers	3957-Answering reviewers.pdf
Copyright License Agreement	3957-Copyright assignment.pdf
Peer-review Report	3957-Peer review(s).pdf
Scientific Editor Work List	3957-Scientific editor work list.doc